Skip to main content
. 2009 Apr 1;20(7):2041–2048. doi: 10.1091/mbc.E08-07-0699

Figure 7.

Figure 7.

Survivin expression counteracts FKHRL1-induced sensitization to doxorubicin and etoposide induced cell death. (A) SH-EP/FKHRL1 cells were treated either with the chemotherapeutics doxorubicin (0.25 μg/ml), etoposide (2.5 μg/ml), and vinblastine (50 ng/ml) alone or in combination with 50 nM 4OHT. Apoptosis was determined by PI-FACS analysis after 24 h. (B) Transgenic Survivin was analyzed by immunoblot analysis. (C) SH-EP and transgenic Survivin-expressing SH-EP-Surv cells were treated with the chemotherapeutics doxorubicin (0.25 μg/ml), etoposide (2.5 μg/ml), and vinblastine (50 ng/ml). Apoptosis was determined by PI-FACS analysis after 48 h. (D and E) SH-EP/FKHRL1-Ctr and SH-EP/FKHRL1-Surv cells were treated either with the chemotherapeutics doxorubicin (0.25 μg/ml) and etoposide (2.5 μg/ml) alone or in combination with 4OHT (50 nM) for 48 and 72 h and analyzed by FACS analysis of PI-stained nuclei. Each panel represents the mean ± SEM of three independent experiments.